although
major
advanc
care
cancer
patient
past
sever
decad
result
improv
surviv
infecti
complic
remain
signific
caus
morbid
mortal
success
identifi
treat
prevent
infect
comprehens
understand
risk
factor
predispos
infect
commonli
encount
pathogen
necessari
addit
clinician
must
keep
abreast
chang
epidemiolog
infect
popul
therapeut
modal
continu
evolv
establish
pathogen
becom
increasingli
drug
resist
new
pathogen
discov
success
manag
infect
continu
present
challeng
year
come
infecti
complic
seriou
caus
morbid
mortal
cancer
patient
especi
underli
hematolog
malign
autopsi
studi
demonstr
approxim
death
infect
relat
although
fewer
data
exist
infecti
mortal
patient
solid
organ
tumor
approxim
patient
estim
infect
either
primari
associ
caus
death
patient
underli
malign
heterogen
group
epidemiolog
review
risk
factor
infect
patient
must
take
account
divers
popul
risk
factor
infect
includ
underli
immun
defici
associ
comorbid
treatmentrel
advers
effect
clearli
one
predispos
factor
may
exist
given
patient
cumul
burden
accur
reflect
risk
infect
extent
howev
risk
factor
associ
specif
infecti
pathogen
understand
individu
risk
factor
help
direct
strategi
diagnosi
treatment
patient
underli
malign
risk
wide
array
infecti
diseas
bacteri
infect
predomin
follow
fungal
infect
viral
infect
occur
infrequ
often
result
reactiv
latent
diseas
primarili
patient
hematolog
malign
parasit
unusu
infect
encount
less
frequent
consid
individu
appropri
exposur
histori
epidemiolog
trend
includ
recognit
emerg
pathogen
syndrom
increas
antimicrobi
drug
resist
commonplac
among
bacteria
fungi
increas
among
virus
astut
clinician
must
remain
awar
emerg
issu
optim
care
cancer
patient
chapter
provid
overview
risk
factor
infect
review
commonli
encount
pathogen
associ
specif
malign
examin
emerg
pathogen
epidemiolog
trend
eas
understand
factor
predispos
infect
divid
host
associ
treatment
associ
hostassoci
factor
includ
underli
immun
defici
medic
comorbid
past
infect
poor
nutrit
statu
psycholog
stress
treatmentassoci
factor
includ
surgeri
radiat
immunosuppress
therapi
antimicrobi
use
invas
procedur
clinician
awar
practic
multipl
defici
usual
encount
simultan
tabl
hostassoci
risk
factor
host
defens
mechan
mediat
immun
system
tradit
thought
compos
two
major
subdivis
innat
non
epidemiolog
infect
cancer
patient
specif
immun
system
adapt
specif
immun
system
categor
somewhat
artifici
system
highli
interrel
despit
literatur
still
describ
system
separ
util
defect
separ
compon
predispos
part
specif
infect
detail
descript
immun
system
beyond
scope
chapter
see
chapter
host
impair
patient
neoplast
diseas
howev
basic
understand
key
compon
innat
adapt
immun
import
clinician
care
patient
malign
tabl
innat
immun
system
constitut
present
antigen
specif
abl
mobil
rapidli
thu
provid
first
line
defens
invad
microorgan
innat
immun
system
compris
anatom
barrier
humor
factor
aid
inflammatori
respons
cellular
compon
facilit
phagocytosi
anatom
barrier
skin
mucou
membran
form
protect
layer
intact
prove
imperm
infecti
agent
protect
process
desquam
skin
epithelium
ciliari
movement
peristalsi
product
tear
saliva
respiratori
gastrointestin
gi
tract
mucu
work
conjunct
barrier
trap
remov
harm
organ
substanc
fatti
acid
found
sweat
lysozym
characterist
discrimin
self
nonself
discrimin
self
nonself
phospholipas
tear
saliva
nasal
secret
defensin
surfact
pulmonari
tract
defensin
gi
tract
inhibit
growth
organ
primarili
bacteria
acid
natur
sweat
gi
secret
also
help
prevent
organ
growth
addit
barrier
normal
flora
site
prevent
colon
pathogen
organ
secret
toxic
substanc
compet
pathogen
bacteria
nutrient
attach
cell
surfac
cancer
patient
barrier
compromis
malign
invas
mechan
obstruct
treatment
radiat
cytotox
chemotherapi
primari
metastat
skin
tumor
increas
risk
skin
soft
tissu
infect
bacteremia
organ
staphylococcu
aureu
coagulaseneg
staphylococci
con
streptococcu
pyogen
corynebacterium
spp
tumor
oral
caviti
nasopharynx
damag
mucosa
result
local
infect
mouth
nose
throat
sinus
predispos
infect
streptococci
haemophilu
influenza
anaerob
necrot
infect
occasion
infect
spread
mening
caus
mening
local
invad
sinus
result
osteomyel
without
subsequ
cerebr
abscess
tumor
gi
tract
invad
mucosa
caus
local
abscess
format
bacteremia
perfor
result
periton
infect
gramneg
bacteria
predomin
howev
fungal
infect
also
encount
primarili
patient
receiv
broadspectrum
antibacteri
agent
gynecolog
malign
disrupt
barrier
femal
genitourinari
gu
tract
predispos
infect
enterococci
enter
aerob
anaerob
gramneg
bacilli
clostridium
spp
anatom
barrier
compromis
cytotox
chemotherapeut
agent
anthracyclin
bleomycin
cytosin
arabinosid
methotrex
like
caus
skin
breakdown
stomat
gi
mucos
dermatolog
side
effect
also
increasingli
report
patient
receiv
thalidomid
radiat
combin
chemotherapi
increas
risk
skin
mucos
toxic
deficit
humor
compon
innat
immun
system
also
predispos
infect
import
compon
includ
complement
coagul
system
substanc
lactoferrin
transferrin
lysozym
interferon
complement
defici
predispos
infect
ineffect
opson
defect
lytic
activ
result
alter
assembl
membran
attack
complex
mac
compon
defici
predispos
infect
encapsul
bacteria
streptococcu
pneumonia
h
influenza
neisseria
meningitidi
mycobacteria
fungi
yeast
saccharomyc
cerevisia
virus
role
complement
defens
viral
infect
suffici
import
pathogen
virus
herpesvirida
coronavirida
develop
strategi
evad
complement
activ
alter
coagul
compromis
vascular
permeabl
diminish
chemotaxi
phagocyt
cell
addit
defici
product
betalysin
plateletderiv
protein
act
cation
deterg
diminish
respons
gramposit
bacteria
lactoferrin
transferrin
bind
iron
essenti
nutrient
bacteria
lysozym
help
break
bacteri
cell
wall
induc
fever
product
acutephas
protein
involv
opson
defici
compon
increas
risk
bacteri
infect
defici
interferon
predispos
viral
infect
vital
limit
viral
replic
within
cell
anatom
humor
defens
breach
cellular
innat
defens
monocytederiv
macrophag
dendrit
cell
mast
cell
natur
killer
cell
granulocyt
ie
neutrophil
eosinophil
basophil
also
respond
rapidli
microbi
challeng
howev
cell
also
initi
modul
respons
b
lymphocyt
serv
import
link
innat
adapt
immun
system
macrophag
exist
throughout
bodi
import
compon
phagocytosi
intracellular
microbi
kill
also
function
antigenpres
cell
apc
present
ingest
foreign
antigen
surfac
cell
immun
system
b
lymphocyt
likewis
dendrit
cell
first
describ
paul
langerhan
ie
langerhan
cell
late
nineteenth
centuri
anoth
essenti
compon
innat
immun
cell
origin
bone
marrow
found
small
quantiti
tissu
contact
extern
environ
skin
respiratori
tract
gi
tract
activ
migrat
lymphoid
organ
also
captur
process
antigen
serv
highli
effici
apc
apc
pattern
recognit
receptor
bind
lipopolysaccharid
peptidoglycan
lipoteicho
acid
mannan
bacteri
dna
doublestrand
rna
collect
refer
pathogenassoci
molecular
pattern
pamp
aid
recognit
pathogen
mast
cell
tradit
recogn
role
allerg
diseas
also
increasingli
acknowledg
import
role
play
protect
infect
leukocyt
found
tissu
bodi
particularli
locat
close
contact
extern
environ
thu
function
earli
immun
sentinel
cell
site
pathogen
entri
contribut
host
defens
directli
phagocytosi
product
reactiv
oxygen
speci
antimicrobi
peptid
indirectli
releas
histamin
vasoact
mediat
increas
vascular
permeabl
blood
flow
action
smooth
muscl
help
increas
expuls
mucos
parasit
enhanc
mucu
product
aid
pathogen
immobil
cytoprotect
mast
cell
also
produc
chemotact
factor
recruit
inflammatori
cell
includ
eosinophil
natur
killer
cell
neutrophil
site
infect
role
protect
parasit
includ
helminth
nematod
protozoa
well
known
recent
role
protect
bacteri
infect
especi
gramneg
infect
establish
evid
mast
cell
help
mediat
antivir
antifung
immun
evid
limit
cancer
patient
receiv
corticosteroid
immunosuppress
agent
decreas
mast
cell
activ
may
compromis
abil
respond
time
manner
parasit
bacteri
infect
natur
killer
cell
nk
cell
lymphoid
cell
unlik
b
cell
lack
antigenspecif
receptor
abl
recogn
cell
self
versu
nonself
kill
infect
stress
host
cell
rapidli
among
earli
respond
infect
origin
recogn
play
major
role
destruct
malign
viral
infect
cell
evid
nk
cell
play
import
role
effect
control
divers
array
pathogen
includ
virus
bacteria
fungi
parasit
mani
infect
contain
absenc
nk
cell
clearanc
organ
almost
alway
effici
complet
presenc
function
nk
cell
respons
neutrophil
singl
import
cell
defens
bacteri
infect
cancer
patient
recruit
site
infect
particip
phagocytosi
intracellular
microbi
kill
neutropenia
commonli
defin
absolut
neutrophil
count
anc
lower
cellsmm
primarili
occur
patient
acut
leukemia
nonhodgkin
lymphoma
receiv
intens
myelosuppress
therapi
underli
malign
part
hematopoiet
stem
cell
transplant
hsct
patient
aplast
anemia
also
like
present
sever
persist
neutropenia
although
unlik
neutropen
patient
hematolog
malign
may
remain
infect
free
prolong
period
although
less
common
solid
organ
tumor
metastat
carcinoma
breast
prostat
lung
adren
thyroid
kidney
infiltr
bone
marrow
result
neutropenia
absolut
neutrophil
count
rapid
declin
neutrophil
count
durat
neutropenia
whether
count
rise
fall
import
determin
infect
risk
larg
multicent
studi
european
organ
research
treatment
cancer
eortc
demonstr
chang
granulocyt
count
import
factor
determin
success
failur
antibiot
therapi
gramneg
bacteremia
patient
whose
granulocyt
count
rise
least
cellsmm
therapi
success
treat
wherea
whose
count
rose
least
cellsmm
complet
resolut
infect
whether
due
invas
progress
malign
treatment
direct
destruct
anatom
barrier
deficit
nonspecif
humor
cellular
immun
diminish
host
frontlin
rapid
respons
infect
adapt
immun
system
antigen
specif
exhibit
immunolog
memori
thu
requir
time
react
mobil
rapidli
although
rapidli
innat
immun
repeat
exposur
organ
adapt
immun
compris
humor
cellular
compon
mediat
b
lymphocyt
respect
humor
immun
mediat
primarili
b
lymphocyt
aris
precursor
stem
cell
bone
marrow
follow
matur
distribut
spleen
lymph
node
proper
antigen
stimul
differenti
immunoglobulin
antibodi
produc
plasma
cell
plasma
cell
produc
opson
antibodi
coat
opson
certain
bacteria
particularli
encapsul
bacteria
greatli
enhanc
phagocytosi
patient
defect
humor
immun
lack
opson
antibodi
common
encapsul
pyogen
bacteria
thu
suscept
infect
organ
pneumonia
h
influenza
n
meningitidi
cellular
immun
mediat
primarili
lymphocyt
lymphocyt
precursor
releas
bone
marrow
migrat
thymu
gland
matur
occur
matur
lymphocyt
exit
thymu
present
circul
lymph
node
spleen
cellmedi
immun
variou
lymphocyt
subset
activ
develop
effector
cell
includ
cytotox
lymphocyt
helper
cell
subset
cell
secret
lymphokin
activ
macrophag
mediat
delayedtyp
hypersensit
respons
cell
secret
lymphokin
stimul
bcell
develop
may
help
activ
cytotox
cell
although
hodgkin
diseas
human
immunodefici
viru
hiv
infect
prototyp
ill
associ
cellular
immun
dysfunct
impair
cellmedi
immun
occur
cancer
includ
acut
chronic
leukemia
solid
organ
tumor
breast
lung
brain
gi
tract
gu
tract
follow
hsct
addit
irradi
medic
azathioprin
cyclosporin
corticosteroid
result
cellular
immunodefici
sever
predominantli
intracellular
pathogen
associ
defici
cellmedi
immun
includ
bacteria
listeria
monocytogen
salmonella
spp
nocardia
asteroid
legionella
mycobacteria
includ
mycobacterium
tuberculosi
nontubercul
mycobacteria
fungi
cryptococcu
neoforman
histoplasma
capsulatum
coccidioid
immiti
pneumocysti
jiroveci
virus
varicella
zoster
viru
vzv
cytomegaloviru
cmv
epsteinbarr
viru
ebv
herp
simplex
viru
hsv
adenoviru
protozoa
toxoplasma
gondii
cryptosporidium
helminth
strongyloid
stercorali
risk
infect
due
compromis
epitheli
mucos
barrier
discuss
addit
risk
also
increas
due
organ
compromis
tumor
invas
mechan
obstruct
surgic
resect
spleen
largest
reticuloendotheli
organ
bodi
contain
monocyt
macrophag
dendrit
cell
natur
killer
cell
b
cell
enabl
perform
mani
import
function
innat
immun
adapt
immun
function
includ
recognit
antigen
clearanc
opson
unopson
particl
bloodstream
product
antibodi
especi
igm
substanc
properdin
import
compon
altern
complement
pathway
tuftsin
peptid
potenti
granulocyt
macrophag
motil
chemotaxi
phagocytosi
cancer
patient
undergon
splenectomi
function
asplen
hsct
recipi
increas
risk
infect
encapsul
bacteria
pneumonia
h
influenza
n
meningitidi
fact
patient
undergo
splenectomi
stage
treatment
hematolog
malign
approxim
risk
develop
overwhelm
sepsi
usual
pneumonia
time
lifetim
although
patient
greatest
risk
sepsi
within
first
two
year
splenectomi
onethird
case
may
occur
five
year
later
case
report
year
patient
undergon
splenectomi
function
asplen
must
instruct
regard
risk
lifethreaten
infect
alert
healthcar
provid
asplen
state
receiv
educ
regard
need
earli
administr
oral
antibiot
therapi
fever
author
recommend
lifelong
prophylact
antibiot
immunosuppress
patient
splenectomi
asplen
patient
undergo
immun
pneumococc
h
influenza
meningococc
influenza
vaccin
addit
vaccin
accord
routin
immun
schedul
patient
primari
metastat
tumor
central
nervou
system
cn
predispos
varieti
infect
either
partial
complet
loss
gag
reflex
increas
risk
aspir
pneumonia
patient
cn
tumor
also
frequent
suffer
impair
micturit
lead
urinari
retent
recurr
urinari
tract
infect
impair
mobil
predispos
skin
breakdown
result
decubitu
ulcer
osteomyel
interestingli
mening
enceph
brain
abscess
uncommon
patient
cn
tumor
unless
relat
problem
surgeri
patient
primari
metastat
lung
tumor
particularli
suscept
recurr
pneumonia
lung
abscess
format
due
decreas
mucociliari
clearanc
bronchial
obstruct
postobstruct
atelectasi
local
invas
malign
head
neck
breast
gastrointestin
genitourinari
tract
also
predispos
infect
flora
resid
site
addit
malign
lymphoma
carcinoma
prostat
ovari
cervix
rectum
commonli
obstruct
urinari
tract
lead
urinari
retent
recurr
urinari
tract
infect
obstruct
biliari
tract
lymphoma
cholangiocarcinoma
pancreat
cancer
predispos
ascend
cholang
tumor
obstruct
blood
vessel
lymph
node
caus
septic
thrombophleb
ischemia
lymphedema
predispos
infect
importantli
obstruct
occur
result
tumor
erad
infect
without
relief
obstruct
usual
unsuccess
increas
infect
risk
note
cancer
patient
certain
chronic
ill
studi
demonstr
patient
type
diabet
hyperglycemia
increas
rate
wound
gu
infect
fungal
infect
candidiasi
rhinocerebr
mucormycosi
shorter
remiss
period
shorter
median
surviv
time
higher
mortal
rate
one
systemat
review
metaanalysi
baron
colleagu
reveal
preexist
diabet
associ
increas
risk
allcaus
mortal
compar
cancer
patient
without
diabet
although
mortal
risk
reach
statist
signific
patient
endometri
breast
colorect
cancer
diabet
appear
pose
addit
mortal
risk
cancer
type
studi
anoth
systemat
review
metaanalysi
baron
et
al
found
cancer
patient
diabet
approxim
like
die
follow
surgeri
nondiabet
counterpart
risk
infect
pulmonari
rhinocerebr
mucormycosi
also
increas
cancer
patient
iron
overload
treat
deferoxamin
obes
also
increas
infect
risk
cancer
patient
especi
undergo
oncolog
surgeri
studi
patient
colon
breast
bone
soft
tissu
tumor
demonstr
patient
morbid
obes
specif
obes
defin
viscer
fat
area
like
suffer
wound
dehisc
surgic
site
infect
cancer
patient
previous
infect
certain
organ
increas
risk
infect
reactiv
especi
undergo
immunosuppress
therapi
thu
obtain
thorough
infecti
diseas
histori
prior
therapi
essenti
popul
question
includ
exposur
home
work
healthcar
set
habit
hobbi
also
thorough
travel
histori
may
provid
clue
otherwis
improb
diagnosi
organ
concern
includ
mycobacterium
tuberculosi
virus
cmv
vzv
hepat
b
fungi
aspergillu
spp
histoplasmosi
blastomycosi
coccidioidomycosi
pneumocysti
jirovecii
parasit
toxoplasma
gondii
stercorali
trypanosoma
cruzii
physician
care
patient
familiar
guidelin
monitor
case
provid
prophylaxi
pathogen
clostridium
difficil
diseas
common
cancer
patient
recur
relaps
primarili
due
ongo
receipt
antimicrobi
agent
howev
chemotherapeut
agent
also
associ
c
difficil
diseas
includ
methotrex
paclitaxel
carboplatin
likewis
previou
infect
andor
colon
drugresist
bacteria
vancomycinresist
enterococci
methicillinresist
aureu
fluoroquinoloneresist
gramneg
bacteria
extendedspectrum
betalactamasecontain
gramneg
bacteria
esbl
increasingli
carbapenemresist
bacteria
pseudomona
aeruginosa
acinetobact
baumannii
klebsiella
pneumonia
risk
factor
subsequ
infect
organ
clinician
awar
past
infect
colon
statu
drugresist
pathogen
help
facilit
empir
antimicrobi
choic
infect
aris
signific
weight
loss
defin
loss
least
bodi
weight
within
month
malnutrit
poor
prognost
indic
common
problem
among
cancer
patient
studi
approxim
patient
lung
cancer
patient
upper
gi
tract
cancer
signific
weight
loss
time
diagnosi
preval
malnutrit
rang
depend
definit
use
underli
malign
instanc
patient
gi
tract
cancer
especi
head
neck
like
suffer
weight
loss
malnutrit
addit
nutrit
statu
often
jeopard
natur
progress
neoplast
diseas
proteincalori
malnutrit
stem
inadequ
intak
carbohydr
protein
fat
meet
metabol
requir
andor
reduc
absorpt
macronutri
common
secondari
diagnosi
individu
diagnos
cancer
mani
factor
lead
condit
includ
anorexia
nausea
vomit
diarrhea
constip
stomat
mucos
dysphagia
alter
tast
smell
pain
depress
anxieti
anorexia
typic
present
cancer
patient
diagnosi
may
occur
side
effect
treatment
almost
univers
patient
wide
metastat
diseas
hasten
progress
cachexia
sever
form
malnutrit
cachexia
character
loss
lean
bodi
mass
muscl
wast
impair
immun
physic
mental
function
estim
immedi
caus
death
cancer
patient
especi
gi
malign
cancer
cachexia
complex
process
thought
result
action
hostand
tumorderiv
factor
increas
evid
anim
model
clinic
studi
support
system
inflammatori
respons
tumor
mediat
part
dysregul
product
proinflammatori
cytokin
induc
acutephas
protein
respons
produc
alter
lipid
carbohydr
metabol
addit
grow
appreci
cachexia
repres
end
product
inappropri
interplay
cytokin
neuropeptid
classic
stress
hormon
intermediari
substrat
metabol
nutrit
defici
associ
increas
risk
infect
increas
antimicrobi
use
increas
hospit
stay
decreas
qualiti
life
increas
mortal
prospect
studi
examin
effect
preoper
enter
immunonutrit
develop
surgic
site
infect
ssi
patient
colorect
cancer
immunonutrit
consist
enter
diet
supplement
arginin
dietari
nucleotid
fatti
acid
given
studi
subject
five
day
prior
bowel
surgeri
ssi
outcom
compar
control
group
patient
receiv
immunonutrit
experienc
fewer
ssi
control
group
similarli
reduc
infect
rate
report
systemat
review
immunonutrit
critic
ill
patient
includ
malign
addit
studi
investig
report
malnutrit
impair
scar
format
increas
risk
surgic
complic
sutur
dehisc
infect
poor
nutrit
statu
preval
portend
wors
outcom
earli
detect
risk
malnutrit
ongo
nutrit
assess
standard
part
qualiti
care
oncolog
practic
decad
clinic
observ
suggest
psycholog
stress
play
role
suscept
respons
certain
infect
recent
rapid
advanc
immunolog
provid
experiment
evid
acut
chronic
stress
alter
immun
respons
viral
challeng
vaccin
respons
wound
heal
one
recent
systemat
review
support
concept
stress
anxieti
depress
risk
factor
acut
viral
respiratori
tract
diseas
acquisit
progress
stress
activ
major
neural
pathway
hypothalamicpituitaryadren
hpa
axi
sympathet
nervou
system
mediat
releas
turn
induc
pronounc
chang
compon
innat
adapt
immun
respons
includ
cytokin
macrophag
natur
killer
cell
lymphocyt
although
individu
respons
stress
vari
chronic
highlevel
stress
experienc
mani
cancer
patient
thought
detriment
much
remain
learn
regard
complex
interplay
physic
health
psycholog
health
patient
although
essenti
patient
care
procedur
treatment
without
risk
follow
treatmentassoci
factor
shown
predispos
patient
underli
malign
increas
risk
infect
extens
surgeri
especi
maxillofaci
gastrointestin
pelvic
region
increas
risk
infect
cancer
patient
although
extens
procedur
often
necessari
especi
advanc
invas
tumor
remov
larg
area
otherwis
protect
tissu
disrupt
anatom
barrier
predispos
leakag
materi
alreadi
contain
bacteri
flora
infecti
complic
follow
surgeri
vari
depend
site
extent
oper
type
procedur
perform
even
postop
infect
shown
one
seri
twice
common
cancer
versu
noncanc
patient
intraabdomin
procedur
hartmann
oper
involv
sigmoid
resect
divert
colostomi
frequent
complic
infect
patient
underli
malign
likewis
cancer
patient
undergo
craniotomi
previous
ventriculoatri
shunt
place
increas
risk
mening
andor
sepsi
extens
surgeri
paranas
sinus
also
shown
predispos
pseudomona
mening
patient
postop
cellul
frequent
report
breast
cancer
surgeri
extent
oper
play
major
role
determin
infect
expect
largest
intervent
associ
maximum
risk
factor
obes
diabet
also
increas
infecti
risk
patient
previous
describ
reduc
infect
rate
may
associ
recent
advanc
minim
invas
surgeri
previous
state
patient
receiv
preoper
immunonutrit
neutropen
enterocol
typhliti
common
gastrointestin
tract
infect
relat
neutropenia
omin
one
review
leukem
patient
incid
major
gastrointestin
complic
includ
typhliti
anoth
studi
estim
incid
typhliti
least
adult
patient
receiv
chemotherapi
solid
malign
tumor
mortal
rate
rang
surgic
manag
patient
typhliti
frequent
encount
although
controversi
issu
along
increas
risk
infect
neutropen
usual
thrombocytopen
patient
high
risk
oper
mortal
surgeri
consequ
care
patient
individu
nonop
manag
bowel
rest
decompress
nutrit
support
broadspectrum
antibiot
often
success
usual
recommend
initi
oper
intervent
typic
reserv
patient
bowel
perfor
uncontrol
hemorrhag
whose
clinic
condit
deterior
despit
conserv
manag
addit
surgeri
preoper
irradi
increas
risk
infect
one
seri
preoper
irradi
given
patient
undergo
surgeri
breast
cancer
associ
twofold
increas
infecti
complic
howev
postop
irradi
associ
increas
risk
infect
also
common
complic
patient
receiv
preoper
irradi
prior
oncolog
surgeri
upper
respiratori
gastrointestin
tract
predominantli
due
fistula
format
impair
wound
heal
well
describ
patient
receiv
radiat
therapi
rectal
cancer
addit
caus
local
tissu
damag
radiat
result
stenos
lesion
lead
obstruct
studi
report
genit
condyloma
follow
pelvic
irradi
therapi
opportunist
infect
p
jirovecii
aspergillu
terreu
cmv
report
follow
use
radiat
combin
temozolomid
alkyl
agent
treatment
glioblastoma
radiat
spleen
lymph
node
depress
cellmedi
immun
antibodi
product
total
bodi
irradi
predict
result
substanti
depress
cellular
immun
function
month
year
result
prolong
marrow
depress
neutropenia
radiat
reaction
radiat
enhanc
radiat
recal
predispos
infect
due
local
tissu
inflamm
breakdown
radiat
enhanc
also
call
radiat
sensit
radiosensit
defin
occur
within
seven
day
radiat
exposur
postul
due
effect
medic
either
enhanc
initi
radiat
tissu
damag
hinder
repair
tissu
exposur
radiat
recal
radiat
recal
dermat
acut
inflammatori
reaction
occur
previous
irradi
area
precipit
initi
certain
drug
primarili
chemotherapeut
agent
definit
occur
seven
day
initi
radiat
exposur
manifest
week
year
initi
radiat
reaction
frequent
result
local
skin
erythema
progress
ulcer
necrosi
although
uncommon
radiat
recal
also
affect
gastrointestin
tract
lung
muscl
brain
chemotherapi
chemotherapeut
agent
predispos
infect
varieti
way
mani
agent
damag
bodi
anatom
barrier
notabl
caus
ulcer
gastrointestin
tract
allow
eros
invas
endogen
microorgan
agent
bleomycin
methotrex
associ
skin
lesion
predispos
bacteremia
staphylococci
skin
flora
agent
bcnu
arac
daunorubicin
irrit
vein
increas
risk
phlebiti
subsequ
bacteremia
mani
chemotherapeut
agent
caus
bone
marrow
suppress
neutropenia
doserel
fashion
drug
also
inhibit
neutrophil
migrat
chemotaxi
regimen
includ
corticosteroid
inhibit
bactericid
activ
neutrophil
humor
immun
alter
agent
methotrex
cyclophosphamid
deferoxamin
ironchel
agent
associ
increas
bacteri
infect
zygomycosi
like
due
increas
avail
free
iron
necessari
fungal
growth
biolog
respons
modifi
brm
natur
occur
substanc
often
use
conjunct
chemotherapeut
agent
help
boost
direct
restor
bodi
immun
respons
cancer
cell
includ
interferon
interleukin
hematopoiet
growth
factor
monoclon
antibodi
compon
vaccin
gene
therapi
nonspecif
immunomodul
agent
bacillu
calmetteguerin
use
treatment
bladder
cancer
levamisol
sometim
use
combin
treat
colon
cancer
immunotherapeut
action
brm
passiv
activ
effect
monoclon
antibodi
passiv
target
antigen
receptor
site
cancer
cell
surfac
antibodi
bind
target
cascad
event
lead
tumor
cell
death
usual
without
invok
immun
respons
convers
brm
work
activ
evok
either
nonspecif
immun
respons
cancer
cell
interferon
interleukin
specif
immun
respons
cancer
vaccin
clinician
awar
advers
effect
brm
especi
monoclon
antibodi
interleukin
interferon
mimic
infect
precipit
flulik
reaction
fever
chill
headach
myalgia
arthralgia
prolong
symptom
howev
prompt
evalu
infect
monoclon
antibodi
alemtuzumab
rituximab
trastuzumab
may
caus
myelosuppress
case
alemtuzumab
profound
persist
lymphopenia
predispos
viral
fungal
infect
one
studi
demonstr
cancer
patient
hiv
receiv
rituximab
addit
chemotherapi
increas
infectionrel
death
increas
rate
opportunist
infect
anoth
studi
demonstr
patient
lymphoma
receiv
rituximab
mainten
therapi
higher
rate
infect
neutropenia
induc
revers
profound
defect
neutrophil
chemotaxi
high
dose
use
treatment
renal
cell
carcinoma
melanoma
associ
infect
rate
consist
primarili
urinari
tract
infect
central
venou
catheterassoci
bloodstream
infect
patient
intact
normal
flora
protect
surfac
skin
mucou
membran
compet
nonindigen
organ
bind
site
produc
substanc
inhibit
kill
microorgan
use
antimicrobi
agent
radic
alter
host
flora
predispos
infect
understand
chang
microbi
flora
import
understand
concept
known
colon
resist
individu
colon
noninvas
flora
sens
consid
protect
normal
flora
prevent
colon
subsequ
infect
invas
pathogen
bacteria
patient
lost
normal
flora
receiv
broadspectrum
antibiot
greater
risk
colon
infect
invas
organ
anim
model
infect
van
der
waaij
elegantli
depict
phenomenon
studi
three
group
mice
use
one
group
render
complet
germ
free
second
group
retain
anaerob
flora
render
free
aerob
third
group
normal
mice
serv
control
mice
given
differ
oral
dose
streptomycinresist
e
coli
eas
detect
persist
colon
determin
evalu
fecal
flora
control
group
requir
e
coli
becom
persist
colon
mice
anaerob
flora
requir
approxim
e
coli
germfre
mice
colon
resist
requir
e
coli
dramat
chang
microbi
flora
also
occur
debilit
patient
studi
johanson
colleagu
throat
cultur
obtain
normal
volunt
patient
hospit
psychiatr
ward
orthoped
ward
two
medic
ward
patient
medic
ward
sever
underli
medic
ill
one
ward
receiv
antibiot
throat
cultur
normal
volunt
psychiatr
patient
reveal
normal
flora
howev
throat
cultur
orthoped
patient
medic
patient
without
antibiot
medic
patient
antibiot
reveal
gramneg
bacilli
suggest
sever
ill
antibiot
hospit
per
se
associ
chang
endogen
flora
fact
predispos
condit
antibiot
use
singl
import
factor
lead
chang
host
flora
although
necessari
infect
prophylaxi
treatment
antimicrobi
agent
caus
rapid
radic
alter
endogen
flora
certain
antimicrobi
agent
penicillin
rifampin
clindamycin
macrolid
bacitracin
vancomycin
significantli
impair
colon
resist
probabl
inhibit
gramposit
nonsporul
lactic
acidproduc
bacilli
bifidobacterium
spp
agent
chlorhexidin
mouthwash
use
minim
plaqu
gingiv
receptor
antagonist
reduc
gastric
acid
also
influenc
microflora
loss
gastric
acid
passag
surviv
oral
flora
alphahemolyt
streptococci
bowel
may
account
part
pathogenesi
cancer
patient
anoth
common
exampl
c
difficil
colon
infect
induc
antibiot
therapi
gener
howev
broadspectrum
antibiot
apt
suppress
normal
noninvas
flora
particularli
anaerob
caus
shift
toward
gramneg
bacteria
yeast
increas
data
demonstr
interact
host
microflora
markedli
dynam
interact
area
intens
research
interest
addit
alter
type
microflora
antimicrobi
use
select
resist
organ
exampl
proven
repeatedli
cancer
patient
histor
trial
nonabsorb
antibiot
use
decreas
colon
alimentari
canal
trial
halt
part
due
emerg
resist
organ
one
studi
surveil
cultur
monitor
patient
receiv
ampicillin
week
nine
patient
becam
rapidli
colon
ampicillinresist
gramneg
bacilli
sever
isol
multipli
drug
resist
one
patient
control
group
acquir
multidrugresist
organ
total
amount
ceftazidim
durat
therapi
number
day
therapi
agent
implic
emerg
vancomycinresist
e
faecium
bacteremia
fluoroquinolon
use
neutropen
cancer
patient
associ
increas
infect
resist
staphylococci
streptococci
anaerob
well
increas
fluoroquinolon
resist
gramneg
bacilli
likewis
incid
antimicrobialresist
fungal
infect
relat
prophylaxi
treatment
fluconazol
prophylaxi
result
develop
resist
strain
c
albican
nonalbican
candida
spp
outbreak
inher
fluconazoleresist
candida
krusei
although
antibiot
use
cancer
patient
essenti
mani
situat
emerg
resist
organ
dramat
increas
directli
link
antibiot
select
pressur
pose
major
health
threat
patient
especi
immunocompromis
procedur
break
natur
protect
barrier
intern
environ
extern
environ
allow
entri
microorgan
predispos
infect
biopsi
bone
marrow
aspir
endoscopi
indwel
vascular
urinari
cathet
exampl
strict
attent
steril
techniqu
applic
decreas
complet
elimin
infecti
risk
associ
procedur
although
indwel
venou
access
devic
commonli
requir
cancer
patient
infect
common
often
sever
complic
year
unit
state
five
million
central
venou
cathet
insert
result
catheterrel
bloodstream
infect
death
risk
infect
vari
devic
use
durat
placement
extent
patient
immunosuppress
gener
risk
infect
greatest
nontunnel
cathet
follow
peripher
insert
central
cathet
picc
tunnel
cathet
implant
port
multilumen
cathet
may
increas
risk
infect
cathet
place
femor
vein
associ
greater
risk
place
subclavian
intern
jugular
vein
decreas
infect
risk
cathet
insert
welltrain
provid
adher
clinic
care
bundl
outlin
step
proper
cathet
insert
mainten
remov
cathet
soon
longer
need
common
caus
pathogen
con
aureu
enterococci
streptococci
candida
spp
although
infect
skin
commens
bacillu
spp
corynebacterium
spp
also
encount
gramneg
bacilli
occur
less
frequent
encount
rapidli
grow
nontubercul
mycobacteria
chelonei
fortuitum
associ
exit
site
tunnel
infect
clinic
diagnosi
infect
difficult
local
sign
symptom
erythema
tender
inconsist
even
present
unreli
indic
cathet
infect
even
immunocompromis
patient
evolut
sign
time
howev
suggest
infect
venou
access
devic
infect
categor
entri
site
infect
tunnel
pocket
infect
catheterassoci
bloodstream
infect
entri
site
infect
often
treat
effect
appropri
antimicrobi
therapi
without
need
cathet
remov
tunnel
pocket
infect
necessit
cathet
remov
well
immedi
initi
empir
antimicrobi
therapi
includ
vancomycin
cover
methicillinresist
aureu
cultur
result
avail
often
especi
difficult
determin
whether
bloodstream
infect
relat
venou
access
devic
frequent
evid
local
cathet
inflamm
seen
recent
howev
concept
differenti
time
posit
use
distinguish
venousaccessdevicerel
infect
type
infect
follow
time
blood
cultur
becom
posit
machin
detect
clinic
microbiolog
laboratori
h
apart
simultan
obtain
cathet
peripher
vein
blood
cultur
cathet
strongli
implic
sourc
infect
although
differenti
may
help
determin
whether
cathet
retain
must
remov
indwel
catheterrel
infect
respond
antimicrobi
therapi
alon
without
cathet
remov
howev
author
suggest
cathet
salvag
attempt
cautious
neutropen
cancer
patient
gramneg
bacteremia
certain
except
notabl
cathet
remov
advis
patient
bloodstream
infect
caus
fungi
nontubercul
mycobacteria
bacteria
decis
concern
need
cathet
remov
depend
sever
clinic
pictur
degre
immunosuppress
avail
altern
vascular
access
site
given
patient
aureu
may
caus
endocard
valu
transesophag
echocardiographi
set
aureu
bloodstream
infect
well
demonstr
determin
durat
therapi
gener
blood
cultur
remain
posit
despit
appropri
antimicrobi
therapi
h
patient
clinic
unstabl
cathet
remov
independ
etiolog
invas
procedur
placement
urinari
cathet
tracheostomi
also
alter
normal
flora
urinari
cathet
becom
colon
organ
track
along
cathet
colon
normal
steril
bodi
site
patient
tracheostomi
gener
becom
colon
gramneg
bacteria
within
day
follow
placement
pneumonia
develop
usual
due
bacteri
pathogen
patient
colon
inde
major
patient
infect
organ
colon
howev
organ
acquir
hospit
studi
demonstr
serial
axillari
surveil
cultur
grow
primarili
epidermidi
corynebacterium
spp
admiss
ill
hospit
progress
howev
resid
flora
shift
toward
gramneg
bacteria
k
pneumonia
p
aeruginosa
e
faecium
less
common
organ
clostridium
septicum
yeast
c
albican
nosocomi
acquir
infect
blood
transfus
occur
despit
modern
blood
bank
techniqu
design
prevent
complic
cancer
patient
especi
hematolog
malign
undergo
hsct
often
requir
sever
transfus
cours
ill
thu
increas
risk
transfusionrel
infect
contamin
blood
product
occur
process
storag
commonli
occur
collect
blood
infect
donor
organ
caus
infect
transfus
patient
must
present
donor
blood
time
collect
produc
symptom
escap
detect
current
screen
method
remain
viabl
citrat
refriger
blood
prolong
period
time
suffici
virul
quantiti
produc
infect
transfus
recipi
virus
frequent
encount
pathogen
associ
blood
transfus
includ
hepat
virus
hiv
ebv
cmv
although
detect
present
screen
procedur
cmv
remain
signific
risk
cancer
patient
protozo
diseas
leishmaniasi
trypanosomiasi
chaga
diseas
microfilari
infect
acquir
transfus
develop
countri
increas
incid
transfusionrel
chaga
diseas
also
report
unit
state
malaria
uncommon
unit
state
occur
especi
peopl
return
travel
endem
area
therefor
transfusionrel
malaria
remain
potenti
risk
countri
babesia
microti
tickborn
protozoan
parasit
transmit
transfus
along
coastal
region
northeastern
unit
state
caus
lifethreaten
infect
immunocompromis
especi
asplen
patient
procedur
store
citrat
blood
prolong
period
greatli
reduc
risk
transfusiontransmit
bacteri
infect
although
store
blood
contain
form
bacteri
contamin
organ
normal
skin
flora
epidermidi
diphtheroid
caus
signific
infect
transfus
recipi
convers
pseudomona
fluorescensputida
yersinia
enterocolitica
surviv
multipli
cold
storag
organ
associ
lifethreaten
sepsi
follow
blood
transfus
platelet
often
store
room
temperatur
enhanc
posttransfus
function
thu
bacteri
infect
like
occur
follow
platelet
transfus
type
malign
statu
malign
ie
activ
remiss
intens
treatment
direct
import
factor
determin
infect
risk
better
data
exist
incid
etiolog
infect
patient
hematolog
malign
especi
undergo
treatment
acut
leukemia
lymphoma
malign
especi
true
patient
develop
neutropenia
result
immunosuppress
therapi
section
outlin
infect
commonli
encount
clinic
practic
stratifi
type
malign
tabl
patient
acut
leukemia
lymphoma
neutropen
either
due
underli
diseas
due
cytotox
chemotherapi
risk
differ
set
infect
neutropen
epidemiolog
infect
neutropen
cancer
patient
undergo
period
chang
often
subject
geograph
institut
factor
howev
certain
trend
consist
approxim
half
episod
neutropen
fever
clinic
site
caus
pathogen
identifi
clinic
sign
infect
pneumonia
cellul
neg
microbiolog
cultur
episod
microbiolog
document
infect
common
site
bloodstream
urinari
tract
respiratori
tract
skin
soft
tissu
gastrointestin
tract
small
proport
gener
less
noninfecti
caus
fever
tumor
drug
fever
identifi
classic
gramneg
bacilli
e
coli
klebsiella
spp
p
aeruginosa
caus
earliest
infect
neutropen
patient
usual
occur
within
first
week
initi
chemotherapi
due
rapid
decreas
neutrophil
count
infect
character
acut
febril
episod
progress
overwhelm
sepsi
treat
promptli
howev
begin
investig
note
rel
decreas
number
gramneg
bacteremia
signific
increas
infect
caus
gramposit
aerob
bacteria
name
staphylococci
streptococci
observ
persist
recent
studi
gramposit
pathogen
caus
approxim
microbiolog
document
infect
bloodstream
infect
consid
gramneg
organ
account
infect
anoth
polymicrobi
isol
anaerob
bacteri
infect
occur
infrequ
fungal
viral
infect
occur
much
later
cours
neutropenia
viral
infect
occur
season
respiratori
viral
infect
sever
reason
increas
gramposit
infect
postul
use
prophylact
empir
antibiot
regimen
target
gramneg
bacteria
diminish
recoveri
gramneg
pathogen
select
gramposit
infect
one
exampl
emerg
streptococc
infect
popul
patient
receiv
fluoroquinolon
use
intravascular
cathet
also
increas
likelihood
infect
gramposit
bacteria
staphylococci
colon
skin
chemotherapeut
regimen
caus
oral
mucos
predispos
infect
bacteria
ordinarili
colon
oropharynx
name
alphahemolyt
streptococci
although
mortal
associ
gramposit
infect
less
gramneg
infect
morbid
signific
exampl
alphahemolyt
streptococci
associ
case
acut
respiratori
distress
syndrom
ard
patient
receiv
cytarabin
furthermor
patient
remain
neutropen
prolong
period
time
like
develop
infect
drugresist
bacteria
enterococcu
spp
corynebacterium
jeikeium
serratia
spp
enterobact
spp
acinetobact
spp
pseudomona
cepacia
stenotrophomona
xanthomona
maltophilia
emerg
consequ
protract
cours
broadspectrum
antibiot
neutrophil
play
major
role
control
infect
due
candida
aspergillu
invas
fungal
infect
also
frequent
encount
neutropen
patient
autopsi
seri
document
invas
fungal
infect
patient
underli
hematolog
malign
besid
prolong
neutropenia
extend
hospit
stay
previou
antibiot
corticosteroid
central
venou
cathet
total
parenter
nutrit
also
risk
factor
fungemia
addit
mani
uncommon
fungi
report
caus
infect
patient
popul
virus
commonli
infect
neutropen
host
reactiv
hsv
far
common
viral
infect
encount
vzv
cmv
adenoviru
viral
hepatitid
also
report
neutropen
patient
acut
leukemia
lymphoma
neutropen
patient
leukemia
lymphoma
common
site
infect
includ
bloodstream
gi
tract
includ
mouth
bowel
perian
region
respiratori
tract
skin
soft
tissu
bacteri
infect
predomin
follow
fungal
infect
viral
infect
parasit
infect
uncommonli
encount
fewer
data
exist
type
infect
encount
nonneutropen
host
one
studi
includ
nonneutropen
patient
leukemia
lymphoma
common
site
infect
respiratori
tract
secondari
bloodstream
infect
due
gramneg
bacilli
gu
tract
primari
bloodstream
infect
encount
less
frequent
neutropen
host
howev
occur
often
due
gramposit
cocci
oral
infect
also
less
common
nonneutropen
host
seri
differ
note
incid
fungal
viral
parasit
infect
investig
demonstr
polymicrobi
bacteremia
common
nonneutropen
host
often
nonneutropen
patient
leukemia
lymphoma
defect
cellmedi
immun
due
either
underli
diseas
treatment
regimen
receiv
cellular
immunodefici
predispos
infect
varieti
intracellular
organ
neutrophil
recoveri
bacteri
infect
caus
l
monocytogen
l
pneumophilia
salmonella
spp
tuberculosi
nontubercul
mycobacteria
nocardia
spp
may
encount
addit
patient
undergon
splenectomi
increas
risk
infect
pneumonia
h
influenza
n
meningitidi
fungal
infect
cryptococcu
occasion
aspergillu
uncommon
aspergillosi
occur
patient
risk
factor
higher
daili
dose
corticosteroid
treatment
renal
failur
often
exist
mucormycosi
rare
occur
nonneutropen
popul
patholog
associ
less
extens
angioinvas
protozo
infect
hand
much
common
nonneutropen
patient
infect
p
jiroveci
gondii
stercorali
cryptosporidium
report
viral
infect
hsv
vzv
cmv
encount
patient
especi
due
reactiv
diseas
chronic
lymphocyt
leukemia
cll
repres
clonal
expans
neoplast
b
lymphocyt
case
matureappear
b
lymphocyt
found
peripher
blood
also
infiltr
bone
marrow
spleen
lymph
node
much
gamma
globulin
produc
patient
cll
nonfunct
lead
defect
humor
immun
hypogammaglobulinemia
may
profound
patient
worsen
diseas
progress
revert
chemotherapi
increas
risk
infect
encapsul
bacteria
pneumonia
h
influenza
n
meningitidi
e
coli
addit
defect
cellmedi
immun
complement
activ
neutrophil
phagocyt
cell
defect
exist
either
due
diseas
result
therapi
treatment
modal
alkyl
agent
without
corticosteroid
predispos
streptococc
staphylococc
enter
gramneg
bacteri
infect
patient
infect
often
occur
mucos
site
especi
respiratori
tract
recurr
infect
common
treatment
purin
analog
monoclon
antibodi
alemtuzumab
predispos
opportunist
infect
listeria
spp
tuberculosi
nocardia
spp
candida
spp
aspergillu
spp
pneumocysti
jiroveci
herpesvirus
recent
progress
multifoc
leukoencephalopathi
pml
caus
jc
viru
describ
cll
patient
treat
purin
analog
fludarabin
variou
monoclon
antibodi
like
cll
patient
multipl
myeloma
mm
classic
present
defect
humor
immun
mm
patient
hypogammaglobulinem
produc
normal
immunoglobulin
normal
rate
therefor
predispos
infect
encapsul
bacteria
pneumonia
h
influenza
n
meningitidi
diseas
progress
malign
plasma
cell
prolifer
within
bone
marrow
extent
marrow
unabl
produc
adequ
number
neutrophil
therefor
patient
advanc
diseas
may
becom
neutropen
increas
risk
gramneg
bacteri
infect
recent
year
howev
advent
new
treatment
modal
hsct
novel
antimyeloma
agent
bortezomib
thalidomid
lenalidomid
improv
outcom
multipl
myeloma
patient
transform
chronic
diseas
result
cumul
immunosuppress
increas
risk
infect
expand
spectrum
potenti
pathogen
patient
popul
includ
infect
c
difficil
cmv
opportunist
mold
chronic
bcell
lymphoprolif
disord
present
cytopenia
major
patient
particular
patient
monocytopenia
granulocytopenia
defect
tcell
function
result
cellular
immunodefici
predispos
varieti
infect
fact
one
studi
major
risk
factor
develop
sever
infect
lymphocytopenia
patient
neutropenia
predispos
gramneg
bacteri
infect
defect
cellmedi
monocytemacrophag
tcell
function
predispos
bacteri
infect
organ
salmonella
listeria
fungal
infect
candida
cryptococcu
viral
infect
hsv
cmv
nontubercul
mycobacteri
infect
kansasii
avium
complex
chelonei
one
review
univers
chicago
five
nine
hairi
cell
leukemia
patient
nontubercul
mycobacteri
infect
dissemin
diseas
present
patient
solid
organ
tumor
risk
infect
patient
underli
hematolog
malign
larg
standard
chemotherapeut
regimen
use
treat
malign
usual
result
either
longterm
profound
neutropenia
except
includ
patient
small
cell
carcinoma
lung
testicular
carcinoma
sarcoma
aggress
chemotherapeut
regimen
use
treat
malign
may
result
period
neutropenia
day
likewis
malign
metastat
carcinoma
breast
prostat
lung
adren
thyroid
kidney
propens
infiltr
bone
marrow
result
neutropenia
advanc
stage
diseas
patient
tumor
central
nervou
system
either
primari
metastat
risk
uniqu
set
infect
base
associ
neurolog
deficit
likewis
solid
organ
tumor
invad
disrupt
anatom
barrier
may
predispos
infect
includ
tumor
skin
oral
caviti
nasopharynx
gastrointestin
respiratori
urogenit
tract
malign
associ
pathogen
discuss
previous
mani
unusu
pathogen
known
infect
patient
underli
immunodefici
especi
patient
hematolog
malign
pathogen
assum
increas
import
cancer
patient
last
year
tabl
global
emerg
antimicrobi
resist
among
bacteria
fungi
virus
viridan
streptococci
gramposit
cocci
part
normal
oral
flora
fast
emerg
pathogen
caus
bacteremia
sepsi
neutropen
patient
especi
patient
aml
undergon
hsct
sever
speci
implic
streptococcu
miti
predomin
speci
miti
also
like
penicillin
fluoroquinolon
resist
rhodococcu
equi
gramposit
coccobacillu
uncommon
pathogen
report
caus
infect
patient
impair
cellular
immun
hiv
infect
common
predispos
risk
factor
howev
cancer
patient
cellular
immunodefici
also
increas
risk
r
equi
frequent
associ
cavitari
pneumonia
may
mimic
fungal
infect
tuberculosi
studi
harvey
sunstrum
surviv
rate
patient
cavitari
pneumonia
receiv
antibiot
alon
compar
receiv
antibiot
surgic
resect
recent
isol
bacteremia
report
patient
underli
malign
associ
central
line
infect
like
due
high
percentag
r
equi
isol
form
heavi
microbi
biofilm
cathet
surfac
gramneg
pathogen
increas
import
cancer
patient
includ
maltophilia
emerg
pathogen
burkholderia
cenocepacia
achromobact
spp
alcaligen
spp
maltophilia
gramneg
bacillu
organ
frequent
isol
environ
particularli
water
suppli
colon
infect
among
immunocompromis
patient
increas
especi
receiv
broadspectrum
antibiot
particularli
carbapenem
maltophilia
caus
pneumonia
urinari
tract
infect
bacteremia
wound
infect
debilit
patient
notori
multidrug
resist
make
treatment
difficult
recent
retrospect
review
maltophilia
infect
hsct
recipi
four
year
israel
maltophilia
infect
major
patient
undergon
allogen
hsct
receiv
carbapenem
previou
month
central
venou
cathet
infect
isol
remain
suscept
trimethoprimsulfamethoxazol
burkholderia
cenocepacia
gramneg
pathogen
primarili
associ
infect
patient
cystic
fibrosi
recent
report
caus
outbreak
cancer
patient
relat
central
venou
cathet
caus
vagin
infect
patient
multipl
myeloma
achromobact
spp
alcaligen
spp
gramneg
bacteria
increasingli
associ
infect
cancer
patient
review
consecut
bacteremia
md
anderson
cancer
center
reveal
patient
underli
hematolog
malign
experienc
neutropenia
achromobact
xylosoxidan
common
pathogen
follow
achromobact
denitrifican
alcaligen
faecali
major
patient
infect
intravascular
cathet
follow
pneumonia
urinari
tract
infect
infect
polymicrobi
concurr
fungemia
isol
suscept
carbapenem
antipseudomon
penicillin
trimethoprimsulfamethoxazol
attribut
mortal
seri
two
emerg
bacteri
syndrom
patient
underli
malign
deserv
mention
first
appear
hypervirul
strain
c
difficil
recent
year
associ
rise
rate
sever
recurr
infect
increas
morbid
mortal
studi
demonstr
chemotherapeut
agent
independ
risk
factor
c
difficil
infect
cdi
diseas
sever
howev
recent
disput
studi
stewart
colleagu
found
patient
cdi
underli
hematolog
malign
longer
length
hospit
stay
differ
rate
colectomi
icu
admiss
death
second
emerg
syndrom
e
coli
pyomyos
increasingli
describ
among
patient
hematolog
malign
pyomyos
typic
caus
gramposit
bacteria
primarili
aureu
howev
review
case
md
anderson
cancer
center
reveal
six
case
e
coli
caus
agent
patient
receiv
chemotherapi
five
neutropen
two
die
despit
receiv
appropri
antimicrobi
therapi
carbapenem
note
isol
resist
fluoroquinolon
produc
extendedspectrum
betalactamas
infect
candida
spp
remain
common
fungal
infect
immunocompromis
cancer
patient
howev
sever
recent
trend
note
incid
nosocomi
candid
fungemia
rose
sharpli
late
earli
institut
candida
fungemia
surpass
enterobacteriacea
pseudomona
spp
enterococcu
spp
candida
albican
still
common
speci
account
approxim
half
fungal
isol
cancer
patient
although
incid
nonalbican
speci
continu
increas
among
c
tropicali
c
parapsilosi
c
glabrata
tend
resist
azol
c
krusei
inher
azol
resist
central
venou
cathet
total
parenter
nutrit
increas
use
azol
antifung
prophylaxi
presum
mechan
thought
account
rise
trend
oral
fungal
infect
c
albican
nonalbican
speci
common
among
patient
cancer
head
neck
particularli
receiv
chemotherapi
radiat
part
treatment
regimen
infect
aspergillu
spp
still
second
common
fungal
infect
among
patient
underli
malign
aspergillu
spp
aspergillu
fumigatu
commonli
isol
speci
caus
invas
diseas
howev
institut
flavu
supplant
fumigatu
common
caus
aspergillosi
clinician
care
cancer
patient
also
awar
emerg
pathogen
terreu
pathogen
close
relat
fumigatu
patient
underli
leukemia
undergon
hsct
pathogen
rel
amphotericin
b
resist
may
respond
better
posaconazol
mani
unusu
fungi
consid
commens
increasingli
recogn
caus
seriou
infect
cancer
patient
organ
includ
trichosporon
spp
fusarium
spp
rhodotorula
spp
saccharomyc
spp
phaeohyphomycosi
nonneoforman
cryptococci
base
recent
review
trichosporon
spp
second
common
caus
fungemia
patient
hematolog
malign
candida
infect
although
report
trichosporon
infect
literatur
attribut
beig
cutaneum
newer
molecular
taxonom
approach
demonstr
exist
numer
speci
trichosporon
includ
three
speci
commonli
isol
clinic
specimen
asahii
inkin
mucoid
trichosporon
spp
primarili
seen
neutropen
patient
hematolog
malign
highdos
corticosteroid
often
caus
central
catheterrel
infect
pulmonari
infect
soft
tissu
infect
treatment
infect
difficult
relaps
common
correct
identif
variou
speci
requir
sequenc
portion
rrna
gene
howev
may
import
clinic
somewhat
distinct
antifung
suscept
profil
particularli
asahii
highli
resist
fluconazol
echinocandin
amphotericin
b
fusarium
spp
caus
sever
often
fatal
infect
neutropen
patient
particularli
undergon
hsct
especi
experi
graft
versu
host
diseas
attribut
mortal
report
one
recent
seri
high
depend
prognost
factor
statu
underli
diseas
sever
lymphopenia
use
steroid
delay
target
therapi
low
albumin
level
fungemia
need
icu
admiss
importantli
delay
neutrophil
recoveri
fusarium
highli
resist
convent
antifung
drug
rise
neutrophil
count
usual
requir
success
respons
voriconazol
drug
choic
fusariosi
recent
data
demonstr
combin
antifung
therapi
better
voriconazol
alon
subsequ
neutropen
episod
associ
high
incid
recurr
rhodotorula
mucilaginosa
also
known
r
rubra
common
caus
rhodotorula
spp
fungemia
follow
r
glutini
r
minuta
case
rhodotorula
spp
infect
patient
underli
malign
catheterassoci
fungemia
follow
endocard
mening
rhodotorula
spp
must
consid
intrins
resist
azol
echinocandin
recent
prophylaxi
treatment
fluconazol
found
risk
factor
rhodotorula
fungemia
patient
receiv
azol
echinocandin
risk
breakthrough
fungemia
risk
factor
rhodotorula
infect
includ
hyperaliment
broadspectrum
antimicrobi
neutropenia
surgeri
treatment
choic
amphotericin
coupl
cathet
remov
crude
mortal
observ
saccharomyc
cerevisia
also
known
baker
yeast
brewer
yeast
widespread
natur
includ
diet
health
food
subtyp
cerevisia
boulardii
also
use
probiot
prepar
prevent
treatment
variou
diarrheal
diseas
associ
c
difficil
parenter
nutrit
invas
infect
due
cerevisia
boulardii
rare
increas
among
cancer
patient
sinc
case
saccharomyc
fungemia
associ
central
venou
cathet
use
receipt
antibiot
therapi
immunocompromis
patient
higher
risk
cerevisia
rather
boulardii
infect
seen
commonli
patient
underli
gi
tract
diseas
icu
isol
cerevisia
one
seri
demonstr
decreas
suscept
amphotericin
azol
deriv
although
break
point
defin
mic
fluconazol
itraconazol
cerevisia
consid
dosedepend
rang
defin
c
albican
hypothes
use
drug
may
play
role
emerg
cerevisia
infect
although
data
scarc
voriconazol
seem
exhibit
good
efficaci
cerevisia
mic
mgl
publish
seri
avail
echinocandin
treatment
preliminari
data
show
good
efficaci
caspofungin
limit
number
cerevisia
strain
despit
spectrum
suscept
favor
outcom
observ
even
amphotericin
b
fluconazol
therapi
coupl
central
venou
cathet
remov
success
clinic
outcom
agent
may
due
low
virul
organ
present
recommend
treatment
includ
withdraw
probiot
regimen
given
administr
antifung
agent
activ
organ
remov
indwel
vascular
cathet
recent
review
phaeohyphomycosi
investig
md
anderson
cancer
center
demonstr
rare
infect
rate
increas
threefold
case
per
patientday
institut
primarili
among
patient
underli
hematolog
malign
dematiac
mold
caus
phaeohyphomycosi
ubiquit
inhabit
soil
encompass
speci
genera
includ
alternaria
bipolari
curvularia
cladosporium
aureobasidium
exserohilium
fonsacea
drechslera
phialophora
hormonema
common
site
infect
lung
sinus
skin
bloodstream
risk
factor
includ
acut
leukemia
receipt
induct
chemotherapi
neutropenia
lymphopenia
allogen
hsct
treatment
highdos
corticosteroid
isol
avail
test
amphotericin
posaconazol
activ
patient
seri
receiv
amphotericin
b
formul
combin
either
azol
echinocandin
undergon
surgeri
primarili
sinu
debrid
resolut
fungemia
seen
patient
cathet
remov
mortal
week
diagnosi
associ
dissemin
infect
bilater
pulmonari
diseas
treatment
amphotericin
b
prepar
breakthrough
infect
coinfect
cmv
treatment
granulocyt
colonystimul
factor
recoveri
neutropenia
within
day
diagnosi
associ
improv
surviv
cryptococcu
gattii
fungu
found
soil
associ
certain
tree
particularli
eucalyptu
tree
previous
found
throughout
tropic
subtrop
region
world
receiv
increas
attent
emerg
pathogen
found
causal
agent
outbreak
vancouv
island
british
columbia
canada
pacif
northwest
area
unit
state
although
caus
syndrom
cryptococcosi
similar
c
neoforman
primarili
manifest
pneumonia
mening
distinct
speci
pathogen
c
gattii
clinic
virul
c
neoforman
caus
multipl
lesion
lung
brain
infect
patient
respond
slowli
therapi
requir
diagnost
followup
evalu
although
diseas
primarili
seen
immunocompet
host
diseas
report
immunocompromis
patient
includ
hivaid
organ
transplant
underli
malign
preliminari
data
suggest
sever
c
gattii
infect
due
defect
induct
host
immun
respons
result
low
level
proinflammatori
cytokin
crucial
control
spread
infect
although
data
limit
despit
antifung
suscept
similar
c
neoforman
vitro
intracrani
infect
c
gattii
associ
neurolog
complic
delay
respons
therapi
higher
incid
neurosurg
intervent
respiratori
viral
infect
rvi
signific
caus
morbid
mortal
patient
underli
malign
develop
new
molecular
techniqu
improv
detect
establish
pathogen
identif
emerg
one
shape
understand
epidemiolog
outcom
rvi
immunosuppress
host
clinician
care
cancer
patient
must
familiar
respiratori
virus
influenza
includ
emerg
pandem
strain
parainfluenza
respiratori
syncyti
viru
human
metapneumoviru
coronavirus
includ
sar
cov
mer
cov
adenoviru
rhinoviru
bocaviru
ki
wu
polyomavirus
associ
upper
lower
respiratori
tract
diseas
popul
incid
rvi
follow
hsct
rang
howev
older
studi
like
underestim
incid
due
less
sensit
detect
methodolog
common
symptom
includ
malais
myalgia
fever
coryza
cough
sore
throat
dyspnea
may
signal
progress
lower
respiratori
tract
lrt
diseas
estim
occur
hsct
patient
studi
suggest
rvi
may
risk
factor
develop
invas
pulmonari
aspergillosi
popul
progress
lrt
diseas
wors
outcom
associ
diagnosi
leukemia
age
year
sever
neutropenia
leukopenia
myeloabl
transplant
cancer
patient
rvi
prolong
shed
creat
risk
transmiss
outbreak
institut
set
addit
respiratori
virus
two
communityacquir
gastrointestin
virus
deserv
mention
hepat
e
viru
hev
infect
reactiv
prolong
viral
shed
develop
cirrhosi
increasingli
report
immunocompromis
host
primarili
among
patient
undergon
solid
organ
transplant
chronic
hev
hsct
recipi
well
studi
given
low
endem
area
world
like
perform
hsct
case
report
patient
acut
leukemia
undergon
hsct
demonstr
prolong
shed
follow
chemotherapi
viral
reactiv
three
month
follow
transplant
given
evid
prolong
viremia
fecal
shed
potenti
exist
nosocomi
transmiss
demonstr
outbreak
franc
addit
hev
chronic
noroviru
infect
emerg
viral
syndrom
patient
underli
malign
especi
hematolog
malign
undergon
hsct
caus
prolong
shed
protract
diseas
popul
patient
shed
viru
remain
symptomat
month
case
year
treatment
support
resolut
diseas
often
requir
decreas
immunosuppress
subsequ
recoveri
cell
hepat
e
viru
prolong
viral
shed
pose
risk
noroviru
transmiss
healthcar
set
reactiv
hepat
b
viru
hbv
hepat
c
viru
hcv
occur
cancer
patient
hbv
reactiv
wellknown
complic
cancer
patient
undergo
cytotox
chemotherapi
immunosuppress
therapi
rate
reactiv
vari
publish
literatur
variat
associ
underli
malign
degre
immunosuppress
use
prophylaxi
patient
underli
hematolog
malign
highest
risk
patient
lymphoma
may
particular
risk
howev
increas
number
case
describ
patient
solid
tumor
especi
breast
hepatocellular
carcinoma
risk
factor
includ
histori
high
serum
viral
load
male
sex
young
age
hbeag
seroposit
use
corticosteroid
use
certain
chemotherapeut
agent
anthracyclin
cyclophosphamid
vinca
alkaloid
use
monoclon
antibodi
rituximab
alemtuzumab
one
seri
use
rituximab
associ
reactiv
case
syndrom
associ
reactiv
vari
wide
rang
asymptomat
diseas
liver
failur
death
mortal
rang
prophylact
agent
lamivudin
adefovir
entecavir
tenofovir
start
earli
possibl
initi
immunosuppress
therapi
hbsag
posit
patient
although
hcv
infect
common
hbv
infect
cancer
patient
hcv
reactiv
follow
immunosuppress
therapi
rare
reactiv
hcv
common
patient
hematolog
malign
report
patient
solid
tumor
undergon
hsct
reliabl
method
exist
predict
individu
patient
risk
reactiv
howev
use
corticosteroid
alon
combin
immunosuppress
agent
tradit
associ
reactiv
diseas
controversi
exist
whether
use
rituximab
risk
factor
hcv
reactiv
clinic
consequ
hcv
reactiv
seem
less
sever
hbv
reactiv
death
report
howev
sever
hepat
secondari
viral
reactiv
develop
mortal
rate
similar
seen
hbv
prophylaxi
current
approv
prevent
hcv
reactiv
patient
popul
antimicrobi
resist
global
crisi
patient
underli
malign
disproport
impact
emerg
trend
drugresist
infect
cost
unit
state
healthcar
system
billion
extra
cost
annual
cost
societi
approxim
billion
year
lost
wage
prematur
death
antibacteri
drug
resist
commonplac
among
cancer
patient
incid
penicillin
resist
among
viridian
streptococci
increas
adult
pediatr
cancer
patient
major
enterococc
isol
colon
allogen
hsct
patient
vancomycin
resist
approxim
vrecolon
hsct
patient
subsequ
develop
clinic
infect
accord
one
recent
studi
vre
lead
caus
bacteremia
first
day
hsct
associ
fourfold
increas
mortal
compar
patient
without
enterococc
bacteremia
addit
daptomycin
resist
also
increas
among
vre
isol
rate
mrsa
increas
among
patient
breast
cancer
cancer
head
neck
center
common
caus
bacteremia
patient
febril
neutropenia
gramneg
bacteri
resist
likewis
increas
seri
e
coli
isol
fluoroquinolon
resist
presenc
extendedspectrum
betalactamaseproduc
enterobacteriacea
carbapenemresist
enterobacteriacea
baumannii
multidrugresist
p
aeruginosa
among
cancer
patient
routin
encount
mention
increas
use
azol
antifung
prophylaxi
thought
play
role
emerg
azoleresist
nonalbican
candida
spp
c
tropicali
c
parapsilosi
c
glabrata
c
krusei
commonplac
patient
popul
although
less
common
antivir
resist
report
among
cmv
hsv
due
prophylact
use
acyclovir
ganciclovir
led
acyclovirand
ganciclovirresist
strain
among
cancer
patient
combat
increas
problem
antimicrobi
resist
clinician
must
know
employ
strategi
infect
prevent
control
antimicrobi
stewardship
patient
care
patient
underli
malign
risk
wide
array
infecti
diseas
caus
signific
morbid
mortal
develop
clear
etiolog
understand
infecti
agent
encount
first
requir
knowledg
hostand
treatmentassoci
factor
predispos
infect
astut
clinician
must
also
awar
new
emerg
infect
patient
popul
new
pathogen
discov
establish
pathogen
becom
increasingli
drug
resist
continu
present
challeng
physician
care
patient
year
ahead
